Well explore: Trends, cost issues and challenges Weight loss Rx return on investment (ROI) PBM solutions and rebate considerations Alternative weight management coverage approaches With GLP-1s, such as Ozempic, Wegovy and others, now a primary cost-driver for employee benefits plans, you cant afford to miss this session!
1 Of the 145,410 patients treated with GLP1 and 291,667 treated with dipeptidyl peptidase 4 (DPP4) inhibitor treatment, 76 and 184, respectively, developed thyroid cancer
Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ
On average, users can lose significant weight, especially when combined with lifestyle changes
Ashley Koff, RD 00:27:28 Often
These are low in calories but high in nutrients